TY - JOUR
T1 - Vascular inflammation in metabolically abnormal but normal-weight and metabolically healthy obese individuals analyzed with 18F-fluorodeoxyglucose positron emission tomography
AU - Yoo, Hye Jin
AU - Kim, Sungeun
AU - Hwang, Soon Young
AU - Hong, Ho Cheol
AU - Choi, Hae Yoon
AU - Seo, Ji A.
AU - Kim, Sin Gon
AU - Kim, Nan Hee
AU - Choi, Dong Seop
AU - Baik, Sei Hyun
AU - Choi, Kyung Mook
N1 - Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
PY - 2015/2/15
Y1 - 2015/2/15
N2 - Recent studies have suggested that body size phenotype may contribute to atherosclerosis and cardiovascular disease. 18F-fluorodeoxyglucose (FDG) positron emission tomography is a useful imaging technique for detecting vascular inflammation that may reflect plaque vulnerability. Therefore, we analyzed which body size phenotypes cause the increased vascular inflammation using FDG positron emission tomography. We compared 18F-FDG uptake, measured using the blood-normalized standardized uptake value, known as the target-to-background ratio (TBR), along with various cardiometabolic risk parameters in 250 participants without a history of cardiovascular disease. Body size phenotypes were classified according to body mass index and the presence/absence of metabolic syndrome. Cardiometabolic risk factors were significantly different among the body size phenotype groups. In particular, the maximum TBR (maxTBR) values in the metabolically abnormal but normal-weight, metabolically healthy obese (MHO), and metabolically abnormal obese groups were significantly greater than those of the metabolically healthy normal-weight (MHNW) group. Components of metabolic syndrome, insulin resistance, high-sensitivity C-reactive protein, and Framingham Risk Score were associated with maxTBR value. Interestingly, although the Framingham Risk Score of the MHO group was almost similar to that of the MHNW group, maxTBR value of MHO subjects was significantly higher than that of MHNW subjects (1.38 [1.20, 1.50] vs 1.22 [1.12, 1.37], p = 0.006). In conclusion, the present study suggests that unique subsets of body size phenotype, such as MHO or metabolically abnormal but normal weight, may have distinct effects on vascular inflammation.
AB - Recent studies have suggested that body size phenotype may contribute to atherosclerosis and cardiovascular disease. 18F-fluorodeoxyglucose (FDG) positron emission tomography is a useful imaging technique for detecting vascular inflammation that may reflect plaque vulnerability. Therefore, we analyzed which body size phenotypes cause the increased vascular inflammation using FDG positron emission tomography. We compared 18F-FDG uptake, measured using the blood-normalized standardized uptake value, known as the target-to-background ratio (TBR), along with various cardiometabolic risk parameters in 250 participants without a history of cardiovascular disease. Body size phenotypes were classified according to body mass index and the presence/absence of metabolic syndrome. Cardiometabolic risk factors were significantly different among the body size phenotype groups. In particular, the maximum TBR (maxTBR) values in the metabolically abnormal but normal-weight, metabolically healthy obese (MHO), and metabolically abnormal obese groups were significantly greater than those of the metabolically healthy normal-weight (MHNW) group. Components of metabolic syndrome, insulin resistance, high-sensitivity C-reactive protein, and Framingham Risk Score were associated with maxTBR value. Interestingly, although the Framingham Risk Score of the MHO group was almost similar to that of the MHNW group, maxTBR value of MHO subjects was significantly higher than that of MHNW subjects (1.38 [1.20, 1.50] vs 1.22 [1.12, 1.37], p = 0.006). In conclusion, the present study suggests that unique subsets of body size phenotype, such as MHO or metabolically abnormal but normal weight, may have distinct effects on vascular inflammation.
UR - http://www.scopus.com/inward/record.url?scp=84921921391&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2014.11.036
DO - 10.1016/j.amjcard.2014.11.036
M3 - Article
C2 - 25529544
AN - SCOPUS:84921921391
SN - 0002-9149
VL - 115
SP - 523
EP - 528
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 4
ER -